In Brief
This article was originally published in The Rose Sheet
Executive Summary
Living Proof says it will expand its existing business and fuel R&D with $30 million in new funds from investors; Sen. Frank Lautenberg announces his plan to retire in 2014, with TSCA reform cited as a priority to cap his career. More news in brief.
You may also be interested in...
Living Proof, Valeant Pharma To Market Strateris Skin Lifter To Doctors
An initial product featuring Living Proof’s Strateris polymer film technology, designed to combat gravity’s effect on aging skin, is slated to launch in March under a joint venture with Valeant Pharmaceuticals. The move will extend Living Proof’s portfolio beyond hair care and provide access to the physician channel.
Living Proof, Valeant Pharma To Market Strateris Skin Lifter To Doctors
An initial product featuring Living Proof’s Strateris polymer film technology, designed to combat gravity’s effect on aging skin, is slated to launch in March under a joint venture with Valeant Pharmaceuticals. The move will extend Living Proof’s portfolio beyond hair care and provide access to the physician channel.
Living Proof, Valeant Pharma To Market Strateris Skin Lifter To Doctors
An initial product featuring Living Proof’s Strateris polymer film technology, designed to combat gravity’s effect on aging skin, is slated to launch in March under a joint venture with Valeant Pharmaceuticals. The move will extend Living Proof’s portfolio beyond hair care and provide access to the physician channel.